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Objectives:We determined the prevalence of classical risk factors for atherosclerosis and mortality risk in
patients with CGI.
Methods: A caseecontrol study was conducted. Patients referred with suspected CGI underwent a stan-
dard work-up including risk factors for atherosclerosis, radiological imaging of abdominal vessels and
tonometry. Cases were patients with confirmed atherosclerotic CGI. Controls were healthy subjects
previously not knownwith CGI. The mortality risk was calculated as standardized mortality ratio derived
from observed mortality, and was estimated with ten-year risk of death using SCORE and PREDICT.
Results: Between 2006 and 2009, 195 patients were evaluated for suspected CGI. After a median follow-
up of 19 months, atherosclerotic CGI was diagnosed in 68 patients. Controls consisted of 132 subjects.
Female gender, diabetes, hypercholesterolemia, a personal and family history of cardiovascular disease
(CVD), and current smoking are highly associated with CGI. After adjustment, female gender (OR 2.14 95%
CI 1.05e4.36), diabetes (OR 5.59, 95% CI 1.95e16.01), current smoking (OR 5.78, 95% CI 2.27e14.72), and
history of CVD (OR 21.61, 95% CI 8.40e55.55) remained significant. CGI patients >55 years had a higher
median ten-year risk of death (15% vs. 5%, P ¼ 0.001) compared to controls. During follow-up of 116
person-years, standardized mortality rate was higher in CGI patients (3.55; 95% CI 1.70e6.52).
Conclusions: Patients with atherosclerotic CGI have an increased estimated CVD risk, and severe excess
mortality. Secondary cardiovascular prevention therapy should be advocated in patients with CGI.
 2012 Elsevier Ireland Ltd. All rights reserved.celiac artery compression
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dardized mortality ratio.
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Chronic gastrointestinal ischemia (CGI) is in the majority of
cases caused by narrowing of the gastrointestinal arteries, with
atherosclerosis being the most common underlying cause [1,2].
Subsequent cardiovascular disease (CVD) preventive therapy is not
considered standard care.
The conventional risk factors for atherosclerosis are: male
gender, age, diabetes mellitus, smoking, hypertension, hypercho-
lesterolemia, medical history of previous CVD, positive family
history of (premature) CVD, obesity, and physical inactivity [3,4].
Any ischemic event is a strong independent risk factor for a new
cardiovascular event [5e11].
Although CGI is considered a manifestation of atherosclerosis,
studies focused on a cardiovascular work-up of classical risk factors
for atherosclerosis in patients with CGI are missing. Previous case
A. Sana et al. / Atherosclerosis 224 (2012) 235e241236series have reported inconsistent findings. A wide range of distri-
bution of classical risk factors for atherosclerosis has been reported
in the baseline characteristics of case series: a 10e93% prevalence
of hypercholesterolemia, 64e92% of hypertension, and 36e72% of
previous coronary artery disease [1,12e18]. The primary objective
of this caseecontrol study was to determine the contribution of
classical atherosclerotic risk factors to atherosclerotic CGI, and the
secondary objective was to assess the mortality risk in treated
patients.
2. Methods
A caseecontrol study was conducted. The Institutional Review
Boards of the Erasmus Medical Center and the Eindhoven hospitals
approved the study. Only patients with written informed consent
entered the present study. Control subjects from the DiaGene Study
population served as controls [19]. DiaGene is a caseecontrol study,
including patients with diabetes (cases) and subjects without
a previous history of diabetes (controls). The DiaGene is conducted
in three general hospitals in Eindhoven, The Netherlands, Controls
were recruited via an advertisement in different local news papers.
Subjects could participate in the study if they were not knownwith
diabetes. Upon registration and after giving their written informed
consent, they received an invite to one of the participating medical
centers. They completed a questionnaire concerning cardiovascular
risk assessment, medical and family history for CVD, medication
use, and smoking. Fasting blood samples were drawn and body
mass index and blood pressure were determined. After obtaining
all the information concerning cardiovascular risk assessment,
there was no further follow-up of the controls. In the current study,
we included the first 132 consecutive subjects who responded for
the DiaGene study as controls. None of these controls were diag-
nosed with CGI.
2.1. Case selection
Consecutive patients with suspected CGI referred to our tertiary
center for evaluation were considered for inclusion. Patients with
intravascular atherosclerotic CGI were included as cases. The full
description of the selection of the cases is described below.
2.2. Diagnosticwork-up including cardiovasculardiagnosticwork-up
All patients referred with suspected CGI underwent a thorough
medical and physical examination, including ECG and with exten-
sive questioning using a structured questionnaire concerning
cardiovascular risk assessment, clinical complaints, weight before
onset of complaints, medical and family history for CVD. During
physical examination, height and weight were measured. From all
patients referred with suspected CGI, venous blood samples were
obtained after 9-h fasting for measurement of serum cholesterol,
triglycerides, LDL-cholesterol, HDL-cholesterol, and blood glucose.
Documented coronary artery disease included at least one of the
following criteria: history of cardiac angina, myocardial infarction
(MI), percutaneous coronary intervention (PCI), or coronary artery
bypass graft surgery (CABG). Documented cerebrovascular accident
included a diagnosis of transient ischemic attack (TIA) or ischemic
stroke. Documented peripheral arterial disease consisted of inter-
mittent claudication previous treatment such as angioplasty,
endovascular stent placement, peripheral arterial bypass graft or
atherectomy. Hypercholesterolemia was considered present when
subjects reported hypercholesterolemia, and/or used a statin in the
absence of CVD, and/or when LDL-cholesterol or total cholesterol
was above the 95th percentile for age and gender. Hypertension
was defined as known with hypertension or using anti-hypertensive medication or a systolic blood pressure >140 mmHg
or a diastolic blood pressure >90 mmHg. Diabetes mellitus was
defined according toWHO criteria or use of blood glucose lowering
agents.
Next to thorough medical and physical examination, all patients
suspected for CGI underwent radiological evaluation by means of
abdominal CT- or MR angiography, and/or conventional angiog-
raphy to visualize the gastrointestinal arteries (celiac artery, supe-
rior mesenteric artery and inferior mesenteric artery) in
combination with functional testing for mucosal perfusion by
means of a 24-h gastric and jejunal tonometry as described before
[2,20,21].
2.3. Consensus diagnosis and definite diagnosis of CGI
Medical history, complaints, and the results of all diagnostic
procedures were discussed in a dedicated multidisciplinary team
consisting of a vascular surgeon, intervention radiologist and
gastroenterologist, all specialized in CGI [21]. The discussion
resulted in a final expert-based consensus diagnosis of CGI or non-
CGI. The consensus diagnosis of CGI was made in presence of 1)
a clinical suspicion of CGI, 2) a significant stenosis (>70%) in at least
one of the gastrointestinal arteries, and 3) detection of mucosal
ischemia by means of 24-h gastric and jejunal tonometry. Patients
with a consensus diagnosis of CGI were classified as having either
occlusive or non-occlusive CGI. Non-occlusive CGI, also called non-
occlusive mesenteric ischemia (NOMI), was defined as gastroin-
testinal ischemia in the absence of significant vascular stenosis.
Patients with occlusive disease were classified as either having an
intravascular stenosis, or extravascular compression due to the
celiac artery compression syndrome (CACS) (see Fig. 1). Patients
diagnosed with NOMI, vascular arteritis and CACS were excluded
from the present analyses. All remaining patients with CGI were
diagnosed with intravascular stenotic or atherosclerotic CGI. These
patients were considered eligible for endovascular or surgical
revascularization. All treated patients were prospectively followed
at the out-patient clinic with regular visits [21]. The definite diag-
nosis of atherosclerotic CGI was made after persistent relief of
symptoms during long-term follow-up of at least 12 months after
initiation of therapy [21]. Patients with definite atherosclerotic CGI
were included as cases in the current study.
2.4. Estimation of ten years risk of death due to cardiovascular
disease
The ten-year mortality risk was estimated in patients without
a history of cardiovascular event, with the SCORE risk system, and
for patients with previous MI and CABG the PREDICT risk score was
used. The PREDICT risk score has been developed for estimating the
6-year mortality risk after hospitalization for acute MI or unstable
angina. It is based on factors such as age, ECG at the time of
hospitalization, comorbidities and renal function. There is no risk
score for estimating the ten-year risk of death due to cardiovascular
event for patients with peripheral artery disease or with a cere-
brovascular event in the past. We estimated the ten-year mortality
in patients with a history of stroke or TIA by using the risk of death
at ten years for these patients as described in the DUTCH transient
ischemic Trial [22].
2.5. Baseline measurements
Venous blood was sampled after 9-h fasting for measurement of
serum cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol,
and blood glucose. Kidney function was categorized according to
Fig. 1. Flow chart of the study
CGI ¼ chronic gastrointestinal ischemia; NOMI ¼ non-occlusive mesenteric ischemia; CACS ¼ celiac artery compression syndrome; CAC ¼ celiac artery compression without
ischemia.
astenotic CGI ¼ CGI in presence of intravascular atherosclerotic stenosis; treated with endovascular stent placement or surgery.
bsymptoms improvement.
cA definite diagnosis of CGI was made if a patient was free of symptoms after adequate therapy for at least 12 months of follow-up;
dsymptoms unchanged despite adequate treatment, n ¼ 9.
eA definite diagnosis of non-CGI was made if a patient was not diagnosed or hospitalized with ischemia related morbidity or mortality after follow-up and if symptoms did not
improve despite adequate treatment.
*CAC, n ¼ 7.
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Disease Outcomes Quality Initiative [23].2.6. Ten year mortality risk and absolute mortality
For the secondary objective we estimated the mortality risk in
patients with atherosclerotic CGI by estimating the ten-year risk of
death due to CVD as well as calculating the all cause mortality as
standardized mortality ratio [24]. We calculated the expected
mortality during follow-up using age and sex specific mortality rates
of the Dutch population. The ten-year risk of death due to CVD was
determined for cases and controls by means of the SCORE risk chart
[25]. For patients with a history of a cardiac event, in particular
myocardial infarction or CABG, the PREDICT risk score [26] was used
to estimate the ten-year risk of death due to CVD. This risk score
systemwas originally developed for estimating the 6-year mortality
risk after hospitalization for acute MI or unstable angina. The latter
score system is based on factors such as age, ECG at the time of
hospitalization, comorbidities and renal function. We estimated the
ten-year mortality risk by deducing it from the 6-year mortality. The
PREDICT project showed that cancer mortality increased to 15% in2e6 years. Subsequently, for estimating the ten-year mortality risk
due to CVD alone, we corrected the calculated ten-yearmortality risk
for the 15%of estimatedmortality riskdue to cancer relatedmortality.
Currently, there is no risk score for estimating the ten-year risk of
mortality due to stroke. A recent cohort study reported the survival of
stroke patients in the DUTCH transient ischemic attack Trial [22]. The
cumulative risk of death at ten years was 47% for patients who pre-
sented with stroke at baseline and 34% for those with TIA. We used
these estimations for ten-year mortality in patients with a history of
stroke or TIA. Thus, themedian (IQR) estimated ten-year risk of death
due to a cardiovascular event was assessed using the SCORE and
PREDICTrisk scores,while themortality risk inpatientswith ahistory
of a cerebrovascular event were based on data from the DUTCH
transient ischemic attack trial [22].2.7. Statistical analyses
Continuous data were described as mean (range), and median
(interquartile range (IQR)) in case of skewed data, and percentages
were given for categorical data. Mean values between patients with
atherosclerotic CGI and controls were compared with student’s
A. Sana et al. / Atherosclerosis 224 (2012) 235e241238T-test or MannWhitney U-test and categorical data were compared
with Chi-square test or Fisher’s exact test. All cause mortality was
calculated as standardized mortality ratio as described previously
[24]. We calculated the 95 percent confidence interval of the
standardized mortality ratio assuming a Poisson distribution of the
observed number of deaths and using exact limits. A two-sided p-
value below 0.05 was considered significant. Missing data of each
variable were not included in the analysis for that specific variable.
Crude and adjusted OR’s and their 95% confidence interval were
estimated using logistic regression models.
3. Results
Between January 2006 and September 2009, a total of 195
patients were referred for evaluation of CGI; see Fig. 1. A consensus
diagnosis of CGI was reached in 131 cases (67% of all referred); 77
(59%) had atherosclerotic CGI and were offered revascularization,
After a median follow-up of 19 (interquartile range 9.50e27.50)
months the definite diagnosis of atherosclerotic CGI was
confirmed in 68 patients, i.e. these patients improved after treat-
ment, and these were used as cases in this study; see Fig. 1. The
remaining nine patients did not have symptom improvement after
revascularization and therefore were not classified as having
a definite diagnosis of atherosclerotic CGI. Theywere excluded from
the analysis. From 68 patients who underwent revascularization:
59 (87%) were treated with percutaneous revascularization, eight
(12%) had surgical revascularization, and one (1%) patient died due
to acute-on-chronic gastrointestinal ischemia before treatment.
Autopsy results showed extensive gastrointestinal arterial athero-
sclerotic disease. There were no differences in age, gender, history
of cardiovascular disease, and risk factors for atherosclerosis
between patients who underwent percutaneous revascularization
or surgery. Thirty-six (53%) patients had single vessel stenosis, and
32 (47%) patients had multi-vessel stenosis. The controls consisted
of 132 subjects. Patients’ and controls’ characteristics are listed in
Table 1. Overall, 1.7% and 0.7% of required data concerning CGI cases
and controls, respectively, were missing. This in particular per-
tained to systolic and diastolic blood pressure levels and glucose,
total cholesterol, LDL-, HDL-cholesterol, and triglyceride levels.Table 1
Crude OR’s in patients with atherosclerotic CGI and controls.
Patient characteristics CGI n ¼ 68
Agea 67 (57e75)
Female gender 47 (69%)
Diabetes 14 (21%)
Hypercholesterolemia 26 (38%)
Hypertension 46 (68%)
Smoking
Never 13 (19%)
Former 25 (37%)
Current 30 (44%)
CVD 35 (52%)
Family history of CVD 35 (52%)
Cholesterol lowering agents 32 (47%)
Anti-hypertensive agents 36 (53%)
Current BMI (kg/m2)a 21.9 (19.3e24.3)
Kidney functionb
Normal or mildly 53 (78%)
decreased low 15 (22%)
Total cholesterol (mmol/l) 4.3 (3.6e5.0)
LDL-cholesterol (mmol/l) 2.2 (1.8e2.8)
CVD ¼ cardiovascular disease; BMI ¼ body mass index; OR ¼ odds ratio; OR is presente
OR are reported with 95 %CI * ¼ P-value < 0.05; ** ¼ P-value < 0.01; *** ¼ P-value < 0.
a Median (IQR 25e75).
b Normal or mildly decreased ¼ GFR 60 90 ml/min/1.73 m2, Low ¼ GFR <90 ml/mi
vascular disease in a first degree relative younger than 60 years.3.1. Univariate and multivariate analysis
The healthy subjects of the DiaGene Study served as a control
population in the current study. As mentioned in the Methods
section, fasting blood samples were drawn from all controls after
recruitment. Five percent of these controls were newly diagnosed
with diabetes mellitus at inclusion. Diabetes, current smoking,
history of CVD, hypercholesterolemia, family history of CVD, the
use of cholesterol lowering agents, and anti-hypertensive agents
were positively associated with atherosclerotic CGI. Females are
more likely than males to have atherosclerotic CGI. The crude
univariate analyses of the distribution of classical risk factors in
patients with atherosclerotic CGI and controls are presented in
Table 1. The odds ratio’s (OR) remained significant for female
gender, diabetes and current smoking after further adjustment of
the selected risk factors for gender, diabetes, hypercholesterolemia,
current smoking, family history of CVD, and kidney function (see
Table 2). The OR for CVD was attenuated after adjustment for
gender (OR 21.61, 95% confidence interval 8.40e55.55).
Atherosclerotic CGI cases had a median weight loss prior to
referral of 9 kg (IQR 6e12 kg). Themedian period of weight loss was
six (IQR 3.8e12.0) months. The BMI of patients with atherosclerotic
CGI was median (IQR) 24.9 (22.2e28.2) (kg/m2) prior to the start of
abdominal complaints, and it decreased to median 21.9 (19.3e24.3)
(kg/m2) at the time of the analysis. LDL-cholesterol levels were
lower in patients with atherosclerotic CGI compared to controls
(see Table 1). Similarly, patients with atherosclerotic CGI had lower
systolic blood pressure levels than in the controls, although well
within the normal range (data not shown). There was no difference
in HDL-cholesterol, triglycerides and glucose between patients
with atherosclerotic CGI and controls (data not shown).
There was no difference in the prevalence of risk factors for
atherosclerosis between atherosclerotic CGI cases with single-
versus multi-vessel stenosis (data not shown). The prevalence of
risk factors between patients with atherosclerotic CGI and a history
of CVD, and those without a history of CVD is presented in Table 3.
Comparing the distribution of risk factors betweenmale and female
with atherosclerotic CGI, female had a significant lower BMI than
male (median 21.1, IQR 17.6e23.3 vs. 23.5, IQR 21.1e27.2, P < 0.05),Controls n ¼ 132 Crude OR
66 (63e72) 0.98 (0.94e1.00)
63 (%) 2.45 (1.32e4.55)**
7 (5%) 4.63 (1.77e12.11)**
32 (24%) 1.94 (1.03e3.64)*
81 (61%) 1.32 (0.71e2.44)
52 (39%) 1.00 Reference
17 (13%) 1.91 (0.90e4.02)
63 (48%) 5.88 (2.48e14.00)***
7 (5%) 18.94 (7.72e46.47)***
43 (33%) 2.20 (1.21e4.00)**
23 (17%) 4.21 (2.19e8.11)***
39 (30%) 2.68 (1.46e4.92)***
25.8 (24.1e28.1) 0.76 (0.69e0.84)**
119 (90%) Reference
13 (10%) 2.59 (1.15e5.83)*
5.2 (4.7e5.9) 0.43 (0.31e0.61)***
3.5 (3.0e4.0)) 0.27 (0.17e0.42)***
d with 95% CI Data are presented as mean (range), unless otherwise specified.
001.
n/1.73 m2 Family history of premature cardiovascular disease is defined as cardio-
Table 2
Multivariate analysis of risk factors for atherosclerosis associated with atheroscle-
rotic CGI
Patient characteristics ORa 95% CI
Female gender 2.14 (1.05e4.36)*
Diabetes 5.59 (1.95e16.01)**
Hypercholesterolemia 1.81 (0.88e3.74)
Hypertension 1.20 (0.58e2.45)
Smoking
Never 1.00 Reference
Former 1.71 (0.76e3.88)
Current 5.78 (2.27e14.72)**
Family history of CVD 1.94 (0.98e3.86)
Kidney function
Normal or mildly decreased 1.00 Reference
Low 2.52 (0.98e6.49)
CVD ¼ cardiovascular disease; OR ¼ odds ratio; CI ¼ confidence interval.
a Adjusted for gender, diabetes, hypercholesterolemia, hypertension, current
smoker, family history of CVD, and kidney function * ¼ P-value <0.05; ** P-value
<0.001; Family history of premature cardiovascular disease is defined as cardio-
vascular disease in a first degree relative younger than 60 years.
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the prevalence of risk factors.
3.2. Mortality risk
The data for estimating the death risk were available in 63 (93%)
out of 68 CGI cases, and 124 (94%) out of 132 controls. The ten-year
mortality risk due to cardiovascular disease was higher in CGI cases
than controls, median (IQR) 8% (2e28) versus 5% (4e8), P ¼ 0.06,
respectively. The median (IQR) ten-year mortality risk in CGI cases
>55 years was significantly higher than in controls, 15% (5e37)
versus 5% (4e8), respectively; P ¼ 0.001.
During a mean follow-up of 7.4 (range 0e31) months, a total of
10 deaths were observed, this was equal to one death per 116
person-years in the CGI group. Three deaths took place within 3
months after the visit to our clinic as a result of acute gastroin-
testinal ischemia (percutaneous revascularization ¼ 1, surgery ¼ 1,
and death before treatment ¼ 1). The remaining seven patients
(percutaneous revascularization n ¼ 6, surgery n ¼ 1) died due to
cancer of respectively the sinus piriformis (n ¼ 1), the small
intestine (n ¼ 1), and lung (n ¼ 1), fatal myocardial infarctionTable 3
Patient characteristics and risk factors for atherosclerosis in atherosclerotic CGI
patients with and without history of CVD.
Patient characteristics With history of
CVD n ¼ 35
Without history
of CVD n ¼ 33
Age, years 70 (62e77)* 65 (51e73)
Male gender 14 (40%) 7 (21%)
Diabetes 12 (34%)** 2 (6%)
Hypercholesterolemia 18 (51%)* 8 (24%)
Hypertension 27 (77%) 19(58%)
Smoking
Never 5 (14%) 8 (24%)
Former 14(40%) 11 (33%)
Current 16 (46%) 14 (43%)
Family history of premature CVD 20 (57%) 15 (46%)
Cholesterol lowering agent 23 (66%)** 9 (27%)
Anti-hypertension agents 24 (69%)** 12 (36%)
Current BMI (kg/m2) 22.6 (20.3e267) 21.3 (18.0e23.3)
Total cholesterol (mmol/l) 4.3 (3.0e4.8) 4.4 (3.6e5.1)
LDL-cholesterol (mmol/l) 2.1 (1.7e2.8) 2.4 (1.9e3.9)
CVD ¼ cardiovascular disease; BMI ¼ body mass index; Data are presented as
median (IQR 25e75), unless otherwise specified; P-values are for controls vs.
atherosclerotic CGI; *p < 0.05, **p < 0.01; Family history of premature cardiovas-
cular disease is defined as cardiovascular disease in a first degree relative younger
than 60 years.(n ¼ 1), terminal heart failure (n ¼ 2), and from an unknown cause
(n ¼ 1). The all cause mortality relative to the Dutch population
standardized for age and calendar period was 3.55 (95 percent
confidence interval, 1.70 to 6.52, P ¼ 0.001). After excluding 3
deaths that took place within 3 months after the visit to our clinic
as a result of acute gastrointestinal ischemia, we observed 7 deaths
in 116 person-years: the SMR of these patients with atherosclerotic
CGI was 2.48 (95 percent confidence interval, 1.01e5.11, P ¼ 0.025).
This severe excess mortality resulted of three patients dying from
cancer (carcinoma of the sinus piriformis, adenocarcinoma of the
small intestine, and lung cancer), one patient having a fatal MI, two
having terminal heart failure, and one dying from an unknown
cause.
4. Discussion
Our study firstly showed that atherosclerotic CGI is associated
with classical risk factors for atherosclerosis. Current smoking,
diabetes, hypercholesterolemia, history and family history of CVD,
and use of cholesterol lowering agents and anti-hypertensive
agents are more prevalent in patients with atherosclerotic CGI.
After adjusting for multiple risk factors diabetes, current smoking,
and previous CVD were significantly associated with atheroscle-
rotic CGI. Female preponderance is confirmed and remains striking.
Secondly, our study shows that patients over 55 years of age with
atherosclerotic CGI have a high risk of ten-year cardiovascular
mortality. This was confirmed during follow-up by severe excess
mortality. Patients with atherosclerotic CGI are at risk for CVD, and
this advocates the strong need to consider secondary preventive
therapy in patients with atherosclerotic CGI.
These results are evenmore striking considering the fact thatmost
patients lost a substantial amount of weight before the baseline
measurement. The measured levels of cholesterol, glucose and blood
pressure inpatientswith atherosclerotic CGIwerenearly normal. This
difference can partly be explained by marked weight loss in most
patients with CGI [1,27], as weight loss is the initial treatment option
for hypercholesterolemia, hypertension and hyperglycaemia. More-
over, the use of cholesterol lowering agents and anti-hypertensive
agents were significantly higher in patients with atherosclerotic CGI
comparing to controls. Fifty-two percent of patients with athero-
scleroticCGIhadknownCVD, and therefore theywere already treated
with cholesterol lowering agents and anti-hypertensive agents.
Therefore, weight loss and higher use of statins in CGI patients,
resulted in lower LDL-cholesterol levels (see Table 1). Similarly, the
weight loss and higher use of anti-hypertensive drugs in CGI patients
resulted in lower systolic blood pressure levels than in the controls,
although well within the normal range (data not shown).
Previous case series comparing endovascular or surgical treat-
ment for CGI, have reported a wide range of prevalences of risk
factors for atherosclerosis, ranging from a 10e93% prevalence of
hypercholesterolemia, 64e92% of hypertension, and 36e72% of
previous coronary artery disease [1,12e18]. This may have been due
to several factors. Firstly, except for one study [16], patients with
CACS were not excluded from the analysis of data in these study
cohorts. Secondly, all studies so far were uncontrolled. We evalu-
ated the risk factors for atherosclerosis systematically at the time of
analysis in our study, including medical and family history, and
laboratory evaluation. Moreover, we used an age-matched control
group to compare the prevalence of risk factors for atherosclerosis.
The healthy control subjects of the DiaGene Study served as
a control population in the current study. The controls were
selected on absence of a known history of diabetes, yet 5% was
newly diagnosed with diabetes at inclusion. This DiaGene cohort
was comparable in age, BMI, and hypertension to two other
population-based studies in the Netherlands: the ERGO study [28]
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Hoorn Study [29] which is a separate cohort of older Dutch subjects.
As such, the DiaGene cohort represents the age-matched general
Dutch population.
A remarkable predominance of female gender in patients with
atherosclerotic CGI was observed. This is in line with earlier reports
of larger cohorts of CGI patients [1,12,14,18]. Earlier case series
reveal high prevalence CACS in women [30e32], however we
excluded patients with CACS in our study. The female preponder-
ance with comparable CVD risk factors, suggests a female specific
anatomical or other susceptibility for ischemia due to intestinal
vascular narrowing. Possible explanations for the female prepon-
derance in CGI patients could be that women with chronic
abdominal pain are more often referred to medical specialists, or
have less potential for collateral circulation and therefore are more
prone to develop CGI.
Patients with atherosclerotic CGI had a marked excess mortality
during follow-up. The severe excess mortality resulted from CVD
and cancer, both related to risk factors for atherosclerosis such as
smoking. This observed mortality was in line with the estimated
risk scores. The ten-year risk of death in all patients was estimated
by combining the SCORE, the PREDICT score, and the DUTCH
transient ischemic Trial. For the PREDICT score, missing ECG data at
the time of the primary CGI event can have resulted in an under-
estimation of 10 year mortality risk and thus have led to a risk
underestimation in the cases. By combining the different risk
scores, we have estimated that patients with atherosclerotic CGI are
at higher risk of cardiovascular mortality than controls. Taken
together, the risk scores seem to have produced valid high risk
estimations, as illustrated by the observed excess mortality.
This study has several limitations. First, our study is a single
center study. Second, patients evaluated for CGI usually represent
a highly selected population. Likely, patients who had more severe
atherosclerotic disease were more likely to be referred for evalua-
tion. And most clinicians will only consider CGI after exclusion of
a variety of other conditions. Our department has a different
setting. During the past 6 years we have set up a referral program
for patients suspected of CGI. The awareness among referring
clinicians and the clinical expertise of our program lowers the
threshold for referral and CGI evaluation, and thus reduces the
selection process prior to referral. Third, it is a relatively small
group for evaluating risk factors for atherosclerosis, the cases
included 68 patients with atherosclerotic CGI. Larger studies are
therefore needed to confirm these results. And fourth, the obser-
vational nature of the study is a limitation, but the incidence of CGI
is so low that decades of patient inclusion would be required for
a sufficiently powered randomized trial.
5. Conclusions
Patients with atherosclerotic CGI have a significant risk for
cardiovascular mortality, resulting from more prevalent classical
risk factors for atherosclerosis. Based on these results and previ-
ously reported cases series, we would advocate CVD preventive
therapy consisting of personalized life-style optimalization, statins,
antihypertensives on indication, and after successful revasculari-
zation and recovery of intestinal mucosal low dose aspirin should
be considered. Future research, most likely observational, is needed
to observe a positive effect of the secondary prevention therapy in
these patients.
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